Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28440518 | 0.85 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL25408509 | 0.85 | — | — | |
| SCHEMBL70685 | 0.82 | — | — | |
| SCHEMBL11419005 | 0.82 | GAA (0.57) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL3370470 | 0.80 | — | — | |
| SCHEMBL6750259 | 0.80 | — | — | |
| Ammonia Solution, Strong SCHEMBL8823685 | 0.80 | — | — | |
| SCHEMBL28807956 | 0.80 | MGAM (0.50) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL11063668 | 0.78 | — | — | |
| Alcohol SCHEMBL28652002 | 0.78 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3207930-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VentiRx Pharmaceuticals, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| CN-106518851-A | Substituted benzoazepines as toll-like receptor modulators | 帆德制药股份有限公司 | 2017-03-22 | — | — | CN | disclosed |
| EP-2663555-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| CN-103562201-B | Substituted benzazepines as modulators of TOLL-like receptors | 帆德制药股份有限公司 | 2016-10-19 | — | — | CN | disclosed |
| US-20140088085-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC (US) | 2014-03-27 | — | — | US | disclosed |
| CN-103562201-A | Substituted benzazepines as modulators of TOLL-like receptors | VENTIRX PHARMACEUTICALS INC | 2014-02-05 | — | — | CN | disclosed |
| EP-2663555-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VentiRx Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2012097177-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088085-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | TLR8, TLR9, TLR1 | MGAM 3055/4885GAA 3674/4885SI 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.